Dive into the archives.
- Dirucotide Does Not Meet Primary Endpoint in Phase III Trial In Secondary Progressive MS
July 27, 2009 – Eli Lilly and Company and BioMS Medical Corp. today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no [...]
- SPMS Treatment Update: Spotlight on dirucotide (BioMS Medical Corp.)
BioMS Medical Announces 2008 Year End Results
Edmonton, Alberta, March 17, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.
“Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look [...]
